Evidence map›Paper›PMID 37569792›Full record

ArticleInternational journal of molecular sciences2023

Design, Synthesis, and Biological Evaluation of New Potential Unusual Modified Anticancer Immunomodulators for Possible Non-Teratogenic Quinazoline-Based Thalidomide Analogs.

Reda R Mabrouk, Abdallah E Abdallah, Hazem A Mahdy, Samar A El-Kalyoubi, Omar Jamal Kamal, Tamer M Abdelghany, Mohamed F Zayed, Heba K Alshaeri, Moudi M Alasmari, Mohamed Ayman El-Zahabi

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Synthesis, antiproliferative evaluation andFuture medicinal chemistry · 2025
    Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Reda R MabroukPharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt.ORCID 0009-0006-2989-4820
Abdallah E AbdallahPharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt.ORCID 0000-0003-2597-7419
Hazem A MahdyPharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt.
Samar A El-KalyoubiDepartment of Pharmaceutical Organic Chemistry, Port Said University, Port Said 42511, Egypt.ORCID 0000-0002-4648-5184
Omar Jamal KamalKing Abdulaziz University Hospital, King Abdulaziz University, Jeddah 21461, Saudi Arabia.ORCID 0009-0003-9872-3150
Tamer M AbdelghanyPharmacology & Toxicology Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt.
Mohamed F ZayedPharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt.ORCID 0000-0001-8683-5460
Heba K AlshaeriPharmaceutical Sciences Department, Fakeeh College for Medical Sciences, Jeddah 21461, Saudi Arabia.ORCID 0000-0003-1960-0092
Moudi M AlasmariCollege of Medicine, King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), Jeddah 21461, Saudi Arabia.
Mohamed Ayman El-ZahabiPharmaceutical Medicinal Chemistry & Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt.ORCID 0000-0003-4538-5840

Funding

Science, Technology & Innovation Funding Authority 43040
6 · The paper itself

Abstract

Sixteen new thalidomide analogs were synthesized. The new candidates showed potent in vitro antiproliferative activities against three human cancer cell lines, namely hepatocellular carcinoma (HepG-2), prostate cancer (PC3), and breast cancer (MCF-7). It was found that compounds XII, XIIIa, XIIIb, XIIIc, XIIId, XIVa, XIVb, and XIVc showed IC

Indexed as

Antineoplastic AgentsThalidomideAdjuvants, ImmunologicApoptosisCell Line, TumorCell ProliferationDose-Response Relationship, DrugDrug Screening Assays, AntitumorHumansImmunologic FactorsMaleMCF-7 CellsMolecular StructureQuinazolinesStructure-Activity RelationshipVascular Endothelial Growth Factor AAdjuvants, ImmunologicAntineoplastic AgentsImmunologic FactorsQuinazolinesThalidomideVascular Endothelial Growth Factor ACRBNimmunomodulatoryquinazolinethalidomide

Identifiers

PMID37569792
PMCPMC10418715

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.